Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

6 years ago
China
In Focus

New Am­pli­tude fund looks to bet over $100 mil­lion on in­cip­i­ent Cana­di­an biotech mar­ket

6 years ago
Financing

Ear­ly da­ta on NextCure's im­muno-on­col­o­gy drug in lung can­cer pa­tients de­lights in­vestors

6 years ago
R&D

Evotec and Vi­for launch joint kid­ney dis­ease ven­ture

6 years ago
Deals

As­traZeneca sketch­es plans for a $1B ven­ture fund — and it's go­ing to Chi­na

6 years ago
Financing
China

Tardy mar­ket­ing ap­pli­ca­tion fil­ing, tri­al fail­ure trou­ble Su­per­nus in­vestors

6 years ago
R&D

Eli Lil­ly, Boehringer In­gel­heim re­vise pro­lif­ic di­a­betes pact, fir­ing all cylin­ders for block­buster Jar­diance ...

6 years ago
Deals

On the heels of a $6.9B As­traZeneca pact, IP dis­pute be­tween Dai­ichi Sankyo and Seat­tle Ge­net­ics rips open in law­suit

6 years ago
R&D
Pharma

Steve Kaf­ka joins Sec­tion 32 as man­ag­ing part­ner; Take­da auc­tions off $660M drug port­fo­lio in bid to re­duce ...

6 years ago
News Briefing

An­oth­er ex-Shire re­search ex­ec heads out, grab­bing top R&D job at deal-hun­gry Ipsen as post-buy­out ex­o­dus con­tin­ues

6 years ago
People
R&D

Andy Plump teams with MD An­der­son on the race to cell ther­a­py 2.0 — and they’re al­ready plan­ning a piv­otal

6 years ago
Deals
R&D

It took a 3-year strug­gle, but No­var­tis fi­nal­ly gets a green light on their copy­cat to Am­gen's big block­buster

6 years ago
R&D

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

6 years ago
R&D

As CRISPR hori­zons cloud, a start­up fo­cus­es on the next big thing with pow­er­house po­ten­tial — the RNA edit­ing ...

6 years ago
Startups

Is FDA do­ing enough to bring biosim­i­lars to mar­ket? Ex­perts dis­cuss

6 years ago
Pharma
FDA+

Make room for poop trans­plants, even if a stool-based ther­a­py is even­tu­al­ly ap­proved — in­sist doc­tors and pa­tients ...

6 years ago
FDA+

Sino Bio­pharm, Or­biMed back Mer­ck-part­nered Ake­so­bio's bet on made-in-Chi­na an­ti­bod­ies

6 years ago
Financing
China

Tmu­ni­ty teams up with On­co­ra Med­ical; T3D re­ceives ad­di­tion­al fund­ing for Alzheimer's study

6 years ago
News Briefing

FDA to Aveo: That's still a 'no' on ti­vo. Aveo: We'll be back.

6 years ago
R&D

As­traZeneca wins ku­dos for pipeline turn­around in a new rank­ing of the top 10 R&D play­ers in the bio­phar­ma world

6 years ago
R&D
Pharma

Sanofi shows off pos­i­tive PhI­II tri­al re­sults for Tou­jeo, open­ing the door to a new group of di­a­betes pa­tients

6 years ago
R&D

As re­sis­tance to stan­dard an­tibi­otics grows, Red­Hill's H. py­lori reg­i­men se­cures FDA ap­proval

6 years ago
R&D
FDA+

Halozyme's lead drug flops in PhI­II, forc­ing CEO to ax 160 and re­set fo­cus on tech plat­form

6 years ago
R&D

Alzheimer's stun­ner: Chi­nese biotech wins OK for a new drug on pos­i­tive da­ta — and they have some high-pro­file ...

6 years ago
China
FDA+
First page Previous page 896897898899900901902 Next page Last page
A service from the Financial Times